Takeda Pharmaceutical Co. $TAK Shares Sold by Summit Global Investments

Summit Global Investments lessened its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 53.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 85,202 shares of the company’s stock after selling 96,451 shares during the period. Summit Global Investments’ holdings in Takeda Pharmaceutical were worth $1,247,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dynasty Wealth Management LLC purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $706,000. Envestnet Portfolio Solutions Inc. grew its holdings in Takeda Pharmaceutical by 29.1% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 15,112 shares of the company’s stock valued at $234,000 after purchasing an additional 3,410 shares during the period. Farther Finance Advisors LLC grew its holdings in Takeda Pharmaceutical by 21.7% in the second quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock valued at $87,000 after purchasing an additional 1,003 shares during the period. Capital Fund Management S.A. increased its position in shares of Takeda Pharmaceutical by 216.1% in the second quarter. Capital Fund Management S.A. now owns 126,279 shares of the company’s stock valued at $1,952,000 after buying an additional 86,333 shares in the last quarter. Finally, QRG Capital Management Inc. raised its stake in shares of Takeda Pharmaceutical by 11.8% during the 2nd quarter. QRG Capital Management Inc. now owns 432,654 shares of the company’s stock worth $6,689,000 after buying an additional 45,726 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.2%

Shares of TAK opened at $17.21 on Friday. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $17.25. The stock has a market cap of $54.76 billion, a PE ratio of 71.71 and a beta of 0.03. The firm’s fifty day moving average is $15.41 and its two-hundred day moving average is $14.81. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 29th. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.07). The business had revenue of $7.76 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.73% and a net margin of 2.58%. Research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating on the stock. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical News Summary

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda raised FY‑2025 revenue guidance to $29.4 billion and issued EPS guidance of 3.160, above consensus revenue expectations — a clear near‑term positive for top‑line visibility and investor sentiment.
• Positive Sentiment: Q3 results beat expectations: EPS $0.95 vs. $0.55 consensus; management cited cost discipline, FX tailwinds and narrowing gap between Growth & Launch products and VYVANSE generic erosion—management is tightening OPEX and raising confidence in the full‑year outlook. Takeda Reports Third-Quarter FY2025 Results
• Neutral Sentiment: CEO Christophe Weber discussed succession planning and avoiding a ‘lame duck’ exit — governance and leadership continuity themes that reduce execution risk but are longer‑term in impact. Takeda’s Christophe Weber on avoiding a ‘lame duck’ succession
• Neutral Sentiment: Earnings‑call and transcript detail product performance, launch timing and cost actions — useful for modeling but not an immediate catalyst. Takeda Q3 FY2025 Earnings Call Transcript
• Negative Sentiment: Analyst downgrade from Buy to Hold after TAK hit 52‑week highs — valuation noted as less compelling and the lack of a clear Entyvio successor reduces near‑term upside; this can pressure sentiment and limit multiple expansion. Takeda Tests New Highs, But Struggles To Find Entyvio Successor
• Negative Sentiment: Legal exposure: an adverse jury outcome in an Actos-related case and active litigation motions (including efforts to move a Louisiana suit) represent potential liabilities and headline risk that can weigh on the stock. Takeda and Eli Lilly fall foul of jury in Actos Pharma company wants La. suit over stomach acid meds moved

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.